| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| sgn-30 | nuclear factor nf-kappa-b p105 subunit | biotech | NA | drugbank | Lymphoma[MeSHID:D008223] Neoplasms[MeSHID:D009369] Lymphoma Non-Hodgkin[MeSHID:D008228] Autoimmune Diseases[MeSHID:D001327] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] |
NA | investigational | unknown |
| sgn-30 | nuclear factor nf-kappa-b p100 subunit | biotech | NA | drugbank | Lymphoma[MeSHID:D008223] Neoplasms[MeSHID:D009369] Lymphoma Non-Hodgkin[MeSHID:D008228] Autoimmune Diseases[MeSHID:D001327] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] |
NA | investigational | unknown |
| sgn-30 | lymphocyte activation antigen cd30 | NA | Successful target | TTD , DGIDB | Lymphoma[MeSHID:D008223] Neoplasms[MeSHID:D009369] Lymphoma Non-Hodgkin[MeSHID:D008228] Autoimmune Diseases[MeSHID:D001327] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] |
21.22 | phase 2 | agonist |
| sgn-30 | lymphocyte activation antigen cd30 | NA | Successful target | TTD , DGIDB | Lymphoma[MeSHID:D008223] Neoplasms[MeSHID:D009369] Lymphoma Non-Hodgkin[MeSHID:D008228] Autoimmune Diseases[MeSHID:D001327] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] |
21.22 | phase 2 | unknown |
| click here to return to the previous page | ||||||||